	US 11,926,654 B2
	Fusion proteins composed of an interleukin-2 mutein and type I interferon
Tays Hernández García, Havana (CU); Maura Lisett Rábade Chediak, Havana (CU); Kalet León Monzón, Havana (CU); Circe Mesa Pardillo, Havana (CU); Luis Enrique Fernández Molina, Havana (CU); and Giselle Hevia Hernández, Havana (CU)
Assigned to CENTRO DE INMUNOLOGIA MOLECULAR, Havana (CU)
Appl. No. 17/052,912
Filed by CENTRO DE INMUNOLOGIA MOLECULAR, Havana (CU)
PCT Filed Mar. 5, 2019, PCT No. PCT/CU2019/050003 § 371(c)(1), (2) Date Nov. 4, 2020, PCT Pub. No. WO2019/214757, PCT Pub. Date Nov. 14, 2019.
Claims priority of application No. 2018-000039 (CU), filed on May 7, 2018.
Prior Publication US 2021/0238246 A1, Aug. 5, 2021
Int. Cl. C07K 14/56 (2006.01); C07K 14/55 (2006.01); C12N 15/62 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/56 (2013.01) [C07K 14/55 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)]

17 Claims

1. A fusion protein comprising an IL2 agonist mutein linked to a human interferon (IFN) α by a linker, wherein the linker consists of a mutated human IgG1 Fc region and a connector peptide.